Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Abivax (AAVXF) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Abivax (AAVXF) over the last 4 years, with Q3 2025 value amounting to $72.5 million.

  • Abivax's Total Non-Current Liabilities changed N/A to $72.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.5 million, marking a year-over-year change of. This contributed to the annual value of $75.5 million for FY2024, which is 7293.09% up from last year.
  • Abivax's Total Non-Current Liabilities amounted to $72.5 million in Q3 2025.
  • Over the past 5 years, Abivax's Total Non-Current Liabilities peaked at $84.1 million during Q2 2024, and registered a low of $17.2 million during Q4 2022.
  • Moreover, its 4-year median value for Total Non-Current Liabilities was $71.3 million (2025), whereas its average is $61.0 million.
  • Per our database at Business Quant, Abivax's Total Non-Current Liabilities soared by 15196.22% in 2023 and then tumbled by 2516.58% in 2025.
  • Abivax's Total Non-Current Liabilities (Quarter) stood at $17.2 million in 2022, then skyrocketed by 151.96% to $43.4 million in 2023, then soared by 73.86% to $75.5 million in 2024, then fell by 3.9% to $72.5 million in 2025.
  • Its Total Non-Current Liabilities was $72.5 million in Q3 2025, compared to $62.9 million in Q2 2025 and $71.3 million in Q1 2025.